正海生物 (300653.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

23.5x

Market Cap

CNY 2.66B

MomentumView details →

1D Return

−1.92%

YTD Return

−25.09%

RSI (14)

49.0

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

23.5x

Market Cap

CNY 2.66B

RSI (14)

49.0

MomentumView details →

1D Return

−1.92%

YTD Return

−25.09%

ProfitabilityView details →

Gross Margin

86.50%

Net Margin

20.28%

EBITDA Margin

32.22%

ROE (TTM)

7.80%

ROA (TTM)

7.03%

Asset Turnover

0.35x

GrowthView details →

Revenue YoY

−6.27%

EPS YoY

−42.13%

FCF YoY

−59.18%

Revenue CAGR 3Y

−5.63%

EPS CAGR 3Y

−28.90%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.11

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

0.14%

Capital & dividendView details →

Debt/Equity

—

Current Ratio

8.42x

Quick Ratio

8.07x

Div Yield

1.87%

Div Rate

CNY 0.28

Div Growth 1Y

−39.13%

Financials snapshotView financials →

Revenue (TTM)

347.75M

Net Income (TTM)

70.53M

Op. CF (TTM)

71.02M

Latest newsMore news →

Zhenghai Bio announced its H1 2026 results: revenue of 160 million yuan, down 14.94% year-on-year; net profit attributable to shareholders of 33.3061 million yuan, down 27.85% year-on-year.12d ago

Similar companies

光华股份001333.SZ 汉邦高科300449.SZ 爱朋医疗300753.SZ 三雄极光300625.SZ 安纳达002136.SZ 海欣食品002702.SZ Find similar companies →

Latest newsMore news →

Zhenghai Bio announced its H1 2026 results: revenue of 160 million yuan, down 14.94% year-on-year; net profit attributable to shareholders of 33.3061 million yuan, down 27.85% year-on-year.12d ago